PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Phase I data suggest PLX3397 is a potential therapy for patients with advanced PVNS

2014-05-15
(Press-News.org) NEW YORK, NY, May 14, 2014 — A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago.

At the time of interim analysis, 11 of 14 evaluable patients (79 percent) had a partial response to the drug and three patients had stable disease. The mean tumor size reduction among all 14 patients was 61 percent.

The drug, PLX3397, is a tyrosine kinase inhibitor that potently inhibits the colony stimulating factor 1 (CSF1) receptor kinase, a driving force in the development and growth of PVNS.

"By taking this drug that potently inhibits a single genetic process, several patients with advanced PVNS appeared to experience, in a relatively short amount of time, relief from pain and stiffness as well as marked improvement in joint function, all with minimal side effects," says William D. Tap, MD, lead author on the study and Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering. "This is a proof-of-principle study that demonstrates the powerful clinical benefit of matching the right drug to the right molecular abnormality and further spurs excitement over the potential of precision medicine."

PVNS is a rare and destructive joint disorder that affects approximately 600 young and middle-aged adults in the United States each year. Patients with PVNS experience an inflammation and overgrowth of the synovium, or joint lining, which results in swelling, pain, and reduced mobility in the affected joint. PVNS is not considered a cancer because it usually remains within a single joint rather than metastasizing, and is not known to cause death. The knee is the most common site affected, followed by the hip.

PVNS tumors express high levels of CSF1, a protein that continually attracts an abundance of cells with CSF1 receptors, such as macrophages, to the joint. This influx of cells causes the inflammation and overgrowth of the joint lining, which can destroy the joint over time.

There are no drugs approved to treat advanced PVNS. Surgery to remove as much of the tumor as possible is the standard of care, with patients sometimes receiving local radiation. However, because these tumors are locally invasive — wrapping around bone, tendons, ligaments, and other parts of the joint — the disease may recur, requiring additional surgery or joint replacements and eventually advancing to the point where it is no longer operable. These patients have few treatment options, among them amputation.

In this study, 23 patients with advanced PVNS in a single joint received 1000 mg of PLX3397 orally each day. Patients underwent an MRI every two months to measure tumor volume using a novel tumor volume score developed for PVNS. Among the 14 patients with evaluable MRI scans, the mean tumor size reduction was 61 percent. Eleven patients experienced a partial response (at least a 50 percent decrease in tumor volume compared to baseline screenings) and three had stable disease. Patients remained on the drug until disease progression or intolerability.

The most common treatment-related side effects were hair-color changes, fatigue, nausea, swelling around the eyes, abnormal taste, diarrhea, vomiting, and decreased appetite.

Dr. Tap will present data from the trial on Sunday, June 1, at the ASCO Annual Meeting.

PLX3397, which received orphan drug designation by the FDA in February 2014, was discovered and is being developed by Plexxikon, who funded the phase I trial. The drug is moving to an international phase III clinical trial, which Dr. Tap is helping to organize.

INFORMATION: About Memorial Sloan Kettering Cancer Center We are the world's oldest and largest private cancer center, home to more than 12,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, we combine 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And our always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, go to http://www.mskcc.org.


ELSE PRESS RELEASES FROM THIS DATE:

Critical access hospitals have higher transfer rates after surgery

2014-05-14
Hospital transfers happened more often after surgery at critical access hospitals (CAHs) but the proportion of patients using post-acute care was equal to or less than that of patients treated at non-CAHs. The CAH designation was created to provide financial support to rural hospitals. As such, they are exempt from Medicare's Prospective Payment System and instead are paid cost-based reimbursement. The proliferation of CAHs after the payment policy change has increased interest in the quality and cost of care these facilities provide. The authors used data from ...

Study examines prenatal exposure to tobacco smoke on inhibition control

2014-05-14
Individuals prenatally exposed to tobacco smoke exhibited weaker response in some regions of the brain while processing a task that measures inhibition control (the ability to control inappropriate responses). Prenatal tobacco smoke exposure is a risk factor for adverse physical and mental outcomes in children. Growing evidence suggests that smoking during pregnancy may increase the risk of psychopathology such as attention-deficit/hyperactivity disorder (ADHD). Research on ADHD has suggested that individuals with the disorder may exhibit poor inhibitory control. Functional ...

Reduction in volume in hippocampus region of brain seen in psychotic disorders

2014-05-14
Reduction in brain volume in the hippocampus (a region related to memory) was seen in patients with the psychotic disorders schizophrenia (SZ), schizoaffective disorder (SZA) and psychotic bipolar disorder (BPP). The pathophysiology of psychotic disorders remains unclear, especially SZ. Changes in volume in the hippocampus are a hallmark of SZ. Advances in image processing allow for the precise parceling of specific hippocampal areas. The authors conducted a neuroimaging study in patients with psychotic disorders and healthy volunteers as part of the multisite ...

MAVEN solar wind ion analyzer will look at key player in Mars atmosphere loss

MAVEN solar wind ion analyzer will look at key player in Mars atmosphere loss
2014-05-14
This past November, NASA launched the Mars Atmosphere and Volatile Evolution (MAVEN) mission in the hope of understanding how and why the planet has been losing its atmosphere over billions of years. One instrument aboard the spacecraft will study a special component of the Martian atmosphere to help solve this mystery. By studying ions, or small electrically charged particles, in and above the Red Planet's tenuous atmosphere, the Solar Wind Ion Analyzer will help answer why Mars has gradually lost much of its atmosphere, developing into a frozen, barren planet. Once ...

Different approaches needed to control cardiovascular disease risks for those with HIV

Different approaches needed to control cardiovascular disease risks for those with HIV
2014-05-14
Even if treated, hypertension and high cholesterol are increasingly common for people with human immunodeficiency virus (HIV), according to a new study from researchers at Mount Sinai St. Luke's and Mount Sinai Roosevelt hospitals in New York and the University of California, Davis. The finding – published online in the Journal of Acquired Immune Deficiency Syndromes – leads the study authors to recommend greater emphasis on cardiology in HIV treatment and research. The study authors examined medical records for a diverse group of 4,278 outpatients in New York City ...

Control methane now, greenhouse gas expert warns

2014-05-14
ITHACA, N.Y. – As the shale gas boom continues, the atmosphere receives more methane, adding to Earth's greenhouse gas problem. Robert Howarth, greenhouse gas expert and ecology and environmental biology professor, fears that we may not be many years away from an environmental tipping point – and disaster. "We have to control methane immediately, and natural gas is the largest methane pollution source in the United States," said Howarth, who explains in an upcoming journal article that Earth may reach the point of no return if average global temperatures rise by 1.5 to ...

Beer foam secrets tapped in new study

2014-05-14
ITHACA, N.Y. – It's an unlikely beer-drinking toast: "Here's to L-T-P-One!" Yet, the secret to optimal foam in the head of a freshly poured brew, according to Cornell food science research, is just the right amount and kind of barley lipid transfer protein No. 1, aka LTP1. Bitter compounds found in hops, like iso-alpha acids, are important to brewers, says Cornell's Karl J. Siebert, principal investigator and author of "Recent Discoveries in Beer Foam," set for publication in next issue of the Journal of the American Society of Brewing Chemists. "Dissolved gases in ...

Extended-release medication offers promise for treating alcohol, opioid dependence

2014-05-14
PORTLAND, Ore. – A comparatively new form of a medication for alcohol and opioid dependence that's injected once a month instead of taken orally once a day appears to be significantly more effective than some other medications – because more patients actually continue the prescribed regimen. The findings, published in the Journal of Substance Abuse Treatment by researchers from Oregon State University and other institutions, offer support for a wider use of medications that may help reduce or prevent substance abuse and related hospital admissions. The cost savings ...

Texas A&M-led study shows how 'body clock' dysregulation underlies obesity, more

2014-05-14
COLLEGE STATION – A team of Texas A&M University System scientists have investigated how "body clock dysregulation" might affect obesity-related metabolic disorders. The team was led by Dr. Chaodong Wu, associate professor in the department of nutrition and food sciences of Texas A&M's College of Agriculture and Life Sciences, and Dr. David Earnest, professor in the department of neuroscience and experimental therapeutics, Texas A&M Health Science Center. Study results were published recently on the Journal of Biological Chemistry website at http://www.jbc.org/content/early/2014/04/25/jbc.M113.539601. "Animal ...

A better way to treat ACE inhibitor angioedema in the ED

2014-05-14
CINCINNATI—Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department. In angioedema, patients experience a rapid swelling of the skin and subcutaneous tissues—which, in some cases, can lead to airway obstruction and suffocation. Physicians usually treat angioedema like an allergic reaction with corticosteroids and antihistamines. But that therapy doesn't always work for another version of the condition, thought to be caused by taking a class of drugs known as ACE inhibitors. ...

LAST 30 PRESS RELEASES:

‘Molecular shield’ placed in the nose may soon treat common hay fever trigger

Beetles under climate stress lay larger male eggs: Wolbachia infection drives adaptive reproduction strategy in response to rising temperature and CO₂

Groundbreaking quantum study puts wave-particle duality to work

Weekly injection could be life changing for Parkinson’s patients

Toxic metals linked to impaired growth in infants in Guatemala

Being consistently physically active in adulthood linked to 30–40% lower risk of death

Nerve pain drug gabapentin linked to increased dementia, cognitive impairment risks

Children’s social care involvement common to nearly third of UK mums who died during perinatal period

‘Support, not judgement’: Study explores links between children’s social care involvement and maternal deaths

Ethnic minority and poorer children more likely to die in intensive care

Major progress in fertility preservation after treatment for cancer of the lymphatic system

Fewer complications after additional ultrasound in pregnant women who feel less fetal movement

Environmental impact of common pesticides seriously underestimated

The Milky Way could be teeming with more satellite galaxies than previously thought

New study reveals surprising reproductive secrets of a cricket-hunting parasitoid fly

Media Tip Sheet: Symposia at ESA2025

NSF CAREER Award will power UVA engineer’s research to improve drug purification

Tiny parasitoid flies show how early-life competition shapes adult success

New coating for glass promises energy-saving windows

Green spaces boost children’s cognitive skills and strengthen family well-being

Ancient trees dying faster than expected in Eastern Oregon

Study findings help hone precision of proven CVD risk tool

Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

Introducing BioEmu: A generative AI Model that enables high-speed and accurate prediction of protein structural ensembles

Replacing mutated microglia with healthy microglia halts progression of genetic neurological disease in mice and humans

New research shows how tropical plants manage rival insect tenants by giving them separate ‘flats’

Condo-style living helps keep the peace inside these ant plants

Climate change action could dramatically limit rising UK heatwave deaths

Annual heat-related deaths projected to increase significantly due to climate and population change

Researchers discover new way cells protect themselves from damage

[Press-News.org] Phase I data suggest PLX3397 is a potential therapy for patients with advanced PVNS